Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL^® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting

April 2, 2024

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL^® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA on April 5-8, 2024. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

Read more